CTRI/2021/05/033622尚未招募未知
A Randomized, Open-label Parallel Group Study to Evaluate Efficacy and Safety of Intravenous Immunoglobulin (IVIG) in Hospitalized patients with COVID-19 - IVIG
ok Nayak Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female subjects in between 18 years to 65 years
- •1.Moderate Illness: Adolescent or adult with presence of clinical features of dyspnea and or hypoxia, fever, cough, including SpO2 <=94% (range: 90-94%) on room air, Respiratory rate more or equal to 24 breaths per minutes. (As per MoHFW)
- •2.Severe Illness: Adolescent or adult with clinical signs of severe Pneumonia plus one of the following; respiratory rate >30 breaths/min, severe respiratory distress, SpO2 <90% on room air. (As per MoHFW)
排除标准
- •Known hypersensitivity to immunoglobulin.
- •History or presence of any disorder that increases the safety risk of the patient as per investigator discretion.
- •History of DVT, PE, thromboembolic stroke or other thrombotic events.
- •Active participant in another research treatment study.
研究者
相似试验
已完成
3 期
A Randomized Open Label, Parallel Group Study to Evaluate the Hemodynamic Effects of Cafedrine/Theodrenaline vs Noradrenaline in the Treatment of Intraoperative Arterial Hypotension in Adults after Induction of General Anesthesia.I95.2I95.9Hypotension due to drugsHypotension, unspecifiedDRKS00028589TEVA-ratiopharm GmbH Medical Affairs223
已完成
不适用
A randomized, open-label, parallel-group study to evaluate the safety and pharmacokinetic characteristics in Korean healthy subjectsKCT0003740Korea Yakult Corporation36
尚未招募
2 期
Study to Assess the Efficacy and Safety of BP08 (Tocilizumab) versus Actemra�®/RoActemra�® plus Standard of Care in Severe COVID-19 patientsCTRI/2021/09/036973CURATEQ BIOLOGICS PRIVATE LIMITED India
进行中（未招募）
1 期
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients with Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)DyslipidemiaMedDRA version: 18.1 Level: PT Classification code 10058108 Term: Dyslipidaemia System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-001934-19-GBSanofi-Aventis Groupe413
进行中（未招募）
1 期
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients with Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)DyslipidemiaEUCTR2015-001934-19-DESanofi-Aventis Groupe420